Barely Significant
← all phrases

“a clear trend”

19,461 sentences · 19,461 papers · 31,348 search hits before verification · confirmed specimen

Sighted at

p<0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

did not reach statistical significancep = 0.1332.7× alphaplainly factual
A clear trend was identified with worse survival rates for the Trifecta group, which did not reach statistical significance: 79.5 ± 0.8% in the Perimount group and 68.1 ± 0.9% in the Trifecta group at 5 years and 76.1 ± 1.3% (PM group) and 63.7 ± 1.9% (TF Group) at 8 years ( p = 0.133, Figure 2 ).
[ 7 ] published in 2017 a single-center 10-year experience of US stenosis after KT, including both reconstructive and endoscopic treatments; they found no differences according to length of stenosis, time between transplant and stenosis or stenosis location; however, there was a clear trend towards a higher success rate in stenosis < 1.5 cm and early management < 3 months, particularly with the use of balloon dilatation, which corresponds with our results.
Demonstrates a clear trend where deeper burial depths lead to lower outlet temperatures ( \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${T_{out}}$$\end{document} ​) due to the more stable and cooler soil temperatures at greater depths.
However, a clear trend was observed: the RR progressively decreased as baseline BEC increased, suggesting a potential therapeutic benefit of mepolizumab for patients with higher levels of eosinophilic inflammation. 2) Confirmatory evidence from the MANTINEE trial The lessons from METREX and METREO informed the design of the MANTINEE trial, a large phase 3 study specifically aimed at confirming the therapeutic benefit of mepolizumab in an eosinophilic COPD population [ 22 ].